atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
atai Life Sciences (Nasdaq: ATAI) will announce its Q3 2022 financial results and provide a business update on November 10, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
atai Life Sciences (Nasdaq: ATAI) will announce its Q3 2022 financial results and provide a business update on November 10, 2022. The announcement comes as atai continues its mission to innovate treatments for mental health disorders. A management interview will be accessible at 8:30 a.m. ET, providing insights into the company's progress and future outlook. Founded in 2018, atai is focused on developing therapeutics for depression, anxiety, and addiction.
Details
News Market Reaction – ATAI
The recorded move for ATAI in the trading session of this news was +14.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its third quarter 2022 financial results and business update on Thursday, November 10, 2022.
A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video will be available in the “Events” section of the atai website at https://www.atai.life/.
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.
atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life
Contact Information
Investor Contact:
Stephen Bardin
Chief Financial Officer
Email: IR@atai.life
Media Contact:
Allan Malievsky
Senior Director of External Affairs
Email: PR@atai.life
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.